These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28090229)

  • 1. The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials.
    De Vecchis R; Cantatrione C; Mazzei D; Barone A; Maurea N
    J Clin Med Res; 2017 Feb; 9(2):130-142. PubMed ID: 28090229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials.
    De Vecchis R; Ariano C
    Cardiovasc Diagn Ther; 2017 Jun; 7(3):272-287. PubMed ID: 28567353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
    De Vecchis R; Cesaro A; Ariano C; Giasi A; Cioppa C
    J Clin Med Res; 2017 Jun; 9(6):488-498. PubMed ID: 28496549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
    De Vecchis R; Cesaro A; Ariano C
    Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
    Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Le HH; El-Khatib C; Mombled M; Guitarian F; Al-Gobari M; Fall M; Janiaud P; Marchant I; Cucherat M; Bejan-Angoulvant T; Gueyffier F
    PLoS One; 2016; 11(2):e0145958. PubMed ID: 26891235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
    Slee A; Saad M; Saksena S
    J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.
    Kalogeropoulos AP; Fonarow GC; Georgiopoulou V; Burkman G; Siwamogsatham S; Patel A; Li S; Papadimitriou L; Butler J
    JAMA Cardiol; 2016 Aug; 1(5):510-8. PubMed ID: 27434402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiopulmonary exercise testing as prognostic indicators: Comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction.
    Sato T; Yoshihisa A; Kanno Y; Suzuki S; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Suzuki H; Saitoh SI; Ishida T; Takeishi Y
    Eur J Prev Cardiol; 2017 Dec; 24(18):1979-1987. PubMed ID: 29086584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and prognosis of patients with different types of heart failure in relation to coronary artery disease].
    Zhou Y; Mo T; Bao YP; Wang L; Zhong RR; Tian JL
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(15):1142-1147. PubMed ID: 32311877
    [No Abstract]   [Full Text] [Related]  

  • 18. Catheter ablation in patients with atrial fibrillation and heart failure with preserved ejection fraction: A systematic review and meta-analysis.
    Siddiqui MU; Junarta J; Riley JM; Ahmed A; Pasha AK; Limbrick K; Alvarez RJ; Frisch DR
    J Arrhythm; 2022 Dec; 38(6):981-990. PubMed ID: 36524044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2).
    Marui A; Nishiwaki N; Komiya T; Hanyu M; Tanaka S; Kimura T; Sakata R;
    Am J Cardiol; 2015 Aug; 116(4):580-6. PubMed ID: 26092271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.